Tekla Capital Management’s Denali Therapeutics DNLI Stock Holding History

Tekla Capital Management’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$9.59M	Hold	324,829	–	–	0.38%	60
2023 Q1	$7.48M	Buy	324,829 +52,309	+19%	+$1.44M	0.28%	66
2022 Q4	$7.58M	Buy	272,520 +50,100	+23%	+$1.49M	0.29%	65
2022 Q3	$6.83M	Hold	222,420	–	–	0.28%	67
2022 Q2	$6.55M	Hold	222,420	–	–	0.26%	75
2022 Q1	$7.16M	Hold	222,420	–	–	0.25%	77
2021 Q4	$9.92M	Hold	222,420	–	–	0.32%	68
2021 Q3	$11.2M	Buy	222,420 +72,334	+48%	+$4.08M	0.36%	68
2021 Q2	$11.8M	Hold	150,086	–	–	0.38%	70
2021 Q1	$8.57M	Buy	150,086 +77,753	+107%	+$5.2M	0.29%	89
2020 Q4	$6.06M	Buy	+72,333	New	+$4.37M	0.21%	108
2019 Q2	–	Sell	-19,372	Closed	-$450K	–	200
2019 Q1	$450K	Buy	+19,372	New	+$405K	0.02%	182

Other funds holding DNLI

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Tekla Capital Management's DNLI Position: Q2 2023 in Review

Tekla Capital Management held its Denali Therapeutics (DNLI) position steady in Q2 2023 at 324,829 shares worth $9.59M. The position accounts for 0.38% of the portfolio, ranked #60.

Tekla Capital Management first reported a position in DNLI in Q1 2019 and has held it in 12 quarters since. The position peaked at $11.8M in Q2 2021. 203 funds tracked by Wall St. Rank hold DNLI as of Q2 2023.

Tekla Capital Management held 324,829 shares of Denali Therapeutics worth $9.59M as of Q2 2023.
Tekla Capital Management left its Denali Therapeutics share count unchanged in Q2 2023.
Denali Therapeutics made up 0.38% of Tekla Capital Management's portfolio in Q2 2023, its #60 holding.
Tekla Capital Management first reported a position in Denali Therapeutics in Q1 2019 and has held it in 12 quarters since.
Tekla Capital Management's Denali Therapeutics position peaked at $11.8M in Q2 2021.
203 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.